Lowering of dietary advanced glycation endproducts (AGE) reduces neointimal formation after arterial injury in genetically hypercholesterolemic mice

Atherosclerosis

Volumn 163, Issue 2, 2002, Pages 303-311

  Lin, Reigh Yi ^a   Reis, Ernane D ^a   Dore, Anthony T ^a   Lu, Min ^a   Ghodsi, Newsha ^a   Fallon, John T ^a   Fisher, Edward A ^a   Vlassara, Helen ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Advanced glycation endproducts; Hypercholesterolemia; Neointimal formation

Indexed keywords

ADVANCED GLYCATION END PRODUCT; APOLIPOPROTEIN E;

ANGIOPLASTY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY INJURY; ARTERY INTIMA PROLIFERATION; ARTERY OCCLUSION; ARTICLE; ATHEROGENESIS; BLOOD VESSEL WALL; CONTROLLED STUDY; DIET; DIET RESTRICTION; DIETARY INTAKE; DISEASE ASSOCIATION; FEMORAL ARTERY; GENETIC ENGINEERING; HYPERCHOLESTEROLEMIA; IN VIVO STUDY; INTIMA; MACROPHAGE; MALE; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; RESTENOSIS; SMOOTH MUSCLE FIBER;

ANIMALS; CONSTRICTION, PATHOLOGIC; DIETARY CARBOHYDRATES; FEMORAL ARTERY; GLYCOSYLATION END PRODUCTS, ADVANCED; HYPERLIPOPROTEINEMIA TYPE II; HYPERPLASIA; MALE; MICE; MICE, INBRED C57BL; TUNICA INTIMA;

EID: 0036275381     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(02)00008-4     Document Type: Article

References (33)

1. Protein glycosylation and the pathogenesis of atherosclerosis
2. Advanced glycation end products induce glomerular sclerosis and albuminuria in normal rats
3. Pathogenic effects of advanced glycosylation: Biochemical, biologic, and clinical implications for diabetes and aging
4. Advanced glycosylation end products in diabetic renal and vascular disease
5. Advanced glycation end products in serum predict changes in the kidney morphology of patients with insulin-dependent diabetes mellitus
6. Nutritional and toxicological aspects of the Maillard browning reaction in foods
7. Metabolic transit of early and advanced Maillard products
8. Physiology and safety aspects of Maillard browning of foods
9. Nutritional consequences of the Maillard reaction. Amino acid availability from fructose-leucine and fructose-trptophan in the rat
10. Advanced glycosylation end products in patients with diabetic nephropathy [see comments]
11. Orally absorbed reactive glycation products (glycotoxins): An environmental risk factor in diabetic nephropathy
12. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells
13. Mouse models of atherosclerosis
14. Mouse model of femoral artery denudation injury associated with the rapid accumulation of adhesion molecules on the luminal surface and recruitment of neutrophils
15. Sulindac inhibits neointimal formation after arterial injury in wild- type and apolipoprotein E-deficient mice
16. Intervening in atherogenesis: Lessons from diabetes
17. Standardizing the immunological measurement of advanced glycation endproducts using normal human serum
18. Dietary glycotoxins: Inhibition of reactive products by aminoguanidine facilitates renal clearance and reduces tissue sequestration
19. Identification of galectin-3 as a high-affinity binding protein for advanced glycation end products (AGE): A new member of the AGE-receptor complex
20. Advanced glycation endproducts promote adhesion molecule (VCAM-1, ICAM-1) expression and atheroma formation in normal rabbits
21. Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. A potential mechanism for the accelerated vasculopathy of diabetes
22. Endothelial receptor-mediated binding of glucose-modified albumin is associated with increased monolayer permeability and modulation of cell surface coagulant properties
23. Differential expression of renal AGE-receptor genes in NOD mice: Possible role in nonobese diabetic renal disease
24. Clinical trials of restenosis after coronary angioplasty
25. Aggressive lipid lowering in postcoronary angioplasty patients with elevated cholesterol (the Lovastatin Restenosis Trial)
26. Advanced products of nonenzymatic glycosylation and the pathogenesis of diabetic vascular disease
27. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications
28. Absence of p-selectin, but not intercellular adhesion molecule-1, attenuates neointimal growth after arterial injury in apolipoprotein e-deficient mice
29. Arterial remodeling. Mechanisms and clinical implications
30. Receptors for proteins modified by advanced glycation endproducts (AGE) - Their functional role in atherosclerosis
31. Advanced glycation end products (AGEs) co-localize with AGE receptors in the retinal vasculature of diabetic and of AGE-infused rats
32. Hemoglobin-AGE: A circulating marker of advanced glycosylation
33. Serum advanced glycosylation end products: A new class of uremic toxins